Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results. Goldsmith KC, Park JR, Kayser K, Malvar J, et al. Nat Med 2023;29:1092-1102.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Goldsmith KC, Park JR, Kayser K, Malvar J, et al. Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results. Nat Med 2023;29:1092-1102.
PMID: 37012551